Suppl video 1 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy

Suppl video 1 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy

<p>Neutrophil migration before and after microbial bioparticle treatment.</p>

Uloženo v:

Podrobná bibliografie
Hlavní autor:	Andrew O. Yam (15293045) (author)
Další autoři:	Jacqueline Bailey (15293048) (author), Francis Lin (15293051) (author), Arnolda Jakovija (15293054) (author), Scott E. Youlten (15293057) (author), Claudio Counoupas (15293060) (author), Matthias Gunzer (15293063) (author), Tobias Bald (15129134) (author), Trent M. Woodruff (15293066) (author), James A. Triccas (15293069) (author), Leonard D. Goldstein (15293072) (author), David Gallego-Ortega (12498107) (author), Shane T. Grey (15293075) (author), Tatyana Chtanova (15293078) (author)
Vydáno:	2025
Témata:	Cancer Tumor Biology Immuno-oncology Methods and Technology Immunology Innate immunity Tumor immunology animal models Immunotherapy Cellular immunotherapy Combination immunotherapy Single Cell Technologies Tumor Microenvironment Host-tumor interactions Immune cells and the microenvironment Inflamation and the microenvironment
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Podobné jednotky

Suppl video 2 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
Autor: Andrew O. Yam (15293045)
Vydáno: (2025)

Suppl video 3 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
Autor: Andrew O. Yam (15293045)
Vydáno: (2025)

Suppl video 4 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
Autor: Andrew O. Yam (15293045)
Vydáno: (2025)

Supplementary Table 1 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
Autor: Andrew O. Yam (15293045)
Vydáno: (2025)

Supplementary video from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
Autor: Min Wu (14962986)
Vydáno: (2025)

Table S1 from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
Autor: Min Wu (14962986)
Vydáno: (2025)

Table S2 from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
Autor: Min Wu (14962986)
Vydáno: (2025)

Table S3 from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
Autor: Min Wu (14962986)
Vydáno: (2025)

Supplementary Data from PP2Ac Deficiency Enhances Tumor Immunogenicity by Activating STING–Type I Interferon Signaling in Glioblastoma
Autor: Isha Mondal (16721699)
Vydáno: (2025)

Supplementary Table from CDK2 Inhibition Enhances Antitumor Immunity by Increasing IFN Response to Endogenous Retroviruses
Autor: Yu Chen (1234761)
Vydáno: (2025)

Supplementary Table from CDK2 Inhibition Enhances Antitumor Immunity by Increasing IFN Response to Endogenous Retroviruses
Autor: Yu Chen (1234761)
Vydáno: (2025)

Supplementary Table from CDK2 Inhibition Enhances Antitumor Immunity by Increasing IFN Response to Endogenous Retroviruses
Autor: Yu Chen (1234761)
Vydáno: (2025)

Supplementary Table from CDK2 Inhibition Enhances Antitumor Immunity by Increasing IFN Response to Endogenous Retroviruses
Autor: Yu Chen (1234761)
Vydáno: (2025)

Table S1 from HDACi-dependent Microenvironmental Normalization Overcomes Tumor Burden–induced T-cell Exhaustion
Autor: Andrew Nguyen (17142197)
Vydáno: (2025)

Supplementary Table S1 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
Autor: Erika Y. Faraoni (14844897)
Vydáno: (2025)

Supplementary Table S3 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
Autor: Erika Y. Faraoni (14844897)
Vydáno: (2025)

Supplementary Table S4 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
Autor: Erika Y. Faraoni (14844897)
Vydáno: (2025)

Supplementary Table S1 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
Autor: Jonathan M.J. Derry (16648337)
Vydáno: (2025)

Supplementary Table S2 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
Autor: Jonathan M.J. Derry (16648337)
Vydáno: (2025)

Supplementary Table S3 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
Autor: Jonathan M.J. Derry (16648337)
Vydáno: (2025)

Supplementary Table S4 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
Autor: Jonathan M.J. Derry (16648337)
Vydáno: (2025)

Supplementary Table S5 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
Autor: Jonathan M.J. Derry (16648337)
Vydáno: (2025)

Supplementary Table S6A from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
Autor: Jonathan M.J. Derry (16648337)
Vydáno: (2025)

Supplementary Table S6B from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
Autor: Jonathan M.J. Derry (16648337)
Vydáno: (2025)

Figure 1 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
Autor: Clare Vesely (505402)
Vydáno: (2025)

Figure 2 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
Autor: Clare Vesely (505402)
Vydáno: (2025)

Figure 3 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
Autor: Clare Vesely (505402)
Vydáno: (2025)

Figure 4 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
Autor: Clare Vesely (505402)
Vydáno: (2025)

Figure 5 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
Autor: Clare Vesely (505402)
Vydáno: (2025)

Table 1 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
Autor: Clare Vesely (505402)
Vydáno: (2025)

Supplementary Data from Attenuation of Sialylation Augments Antitumor Immunity and Improves Response to Immunotherapy in Ovarian Cancer
Autor: Kankan Cao (16437263)
Vydáno: (2025)

Supplementary Tables S2-13 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
Autor: Francisco Hermida-Prado (14958909)
Vydáno: (2025)

Supplementary Table S1 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
Autor: Hansol Lee (15054787)
Vydáno: (2025)

Supplementary Table S2 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
Autor: Hansol Lee (15054787)
Vydáno: (2025)

Supplementary Table S3 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
Autor: Hansol Lee (15054787)
Vydáno: (2025)

Supplementary Table S4 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
Autor: Hansol Lee (15054787)
Vydáno: (2025)

Figure S1 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
Autor: Li-Li Long (14963775)
Vydáno: (2025)

Figure S2 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
Autor: Li-Li Long (14963775)
Vydáno: (2025)

Figure S3 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
Autor: Li-Li Long (14963775)
Vydáno: (2025)

Figure S4 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
Autor: Li-Li Long (14963775)
Vydáno: (2025)

Cannot write session to /tmp/vufind_sessions/sess_8i1l53h8gi9k7jfkvc7d0vd90d